Summary by Moomoo AI
Wuxi Pharmaceutical Ming Kand New Drug Development Co., Ltd. repurchased shares through the Shanghai Stock Exchange from March 8 to April 12, 2024. The company repurchased multiple A shares during this period, bringing the total number of repurchases to millions of shares. The repurchase price presents a different degree of discount or premium compared to the market price. This action was made in accordance with the relevant rules and disclosed to the Hong Kong Stock Exchange Limited on 12 April 2024. The Director of the Company, Li Gem, confirmed that all transactions have been executed in accordance with the requirements and have been formally authorized by the Board of Directors.